A Study of Tumor-Treating Fields (TTFields) in People with Lung Adenocarcinoma


Full Title

A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients with Early-Stage Resectable Lung Adenocarcinoma


Researchers want to see if tumor-treating fields (TTFields) are safe and practical for people with lung adenocarcinoma before surgery. Lung adenocarcinoma is a type of lung cancer. If you join this study, you will get treatment with TTFields for up to 3 weeks before lung cancer surgery.

TTFields are low-energy electric fields. They are given through insulated electrode arrays (patches) that are placed on the skin. TTFields can disrupt the ability of cancer cells to divide. Some lab studies have also shown that TTFields may help the body’s natural defenses to fight cancer.

The TTFields treatment in this study will be given through a device called the NovoTTF-200T System. This device is portable, meaning it is lightweight and you can carry it around with you. For example, it can be carried in an over-the-shoulder bag or backpack.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have lung adenocarcinoma that will be taken out with surgery.
  • Have a tumor that is 2 cm or larger in size.
  • Have no history of heart rhythm problems or pacemaker use.
  • Be age 22 or older.


For more information or to see if you can join this study, please call Dr. Prasad Adusumilli’s office at 212-639-8093.




Phase I (phase 1)

Disease Status

Newly Diagnosed


ClinicalTrials.gov ID